Skip to main content
TipRanks
Go Ultimate75% OFF

Amylyx Pharmaceuticals Inc (AMLX) AI Stock Analysis

725 Followers
AMLX

Amylyx Pharmaceuticals Inc

(NASDAQ:AMLX)

Select Model
Rating:54Neutral
Price Target:$32.00â–²(22.14% Upside)
Action:reiterated
Date:11/05/26

The score is held down primarily by deteriorated financial performance (revenue collapsing to $0, multi-year losses, and significant cash burn), partially offset by a strong balance sheet and a highly positive earnings call centered on Phase III success and an on-track NDA timeline. Technicals are neutral and valuation is constrained by negative earnings.

Positive Factors
Phase III clinical validationAvexitide’s statistically significant Phase III efficacy and clinically meaningful reductions across primary and secondary endpoints materially strengthen the lead program. The results support regulatory progress and provide a stronger foundation for a potential commercial product in an area with substantial unmet medical need.
Negative Factors
Revenue collapse and sustained lossesThe disappearance of reported revenue after RELYVRIO’s withdrawal leaves Amylyx without an established commercial revenue stream in the latest periods. Continued net losses make future performance highly dependent on successful avexitide development, approval, and eventual market adoption.

Amylyx Pharmaceuticals Inc (AMLX) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%AMLX+76.79%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.42B
Dividend Yield
―
Average Volume (3M)
1.67M
Price to Earnings (P/E)
-18.7
Beta (1Y)
0.93
Revenue Growth
―
EPS Growth
19.61%
Country
US
Employees
136
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Amylyx Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipelin...

How the Company Makes Money

As of the latest available public information, Amylyx’s revenue model is primarily tied to the commercialization of its lead product and, secondarily, to potential collaboration-related income. Product revenue: Amylyx previously generated sales from...

Amylyx Pharmaceuticals Inc Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-10.88%|Next Earnings Date:Mar 09, 2027
Earnings Call SentimentPositive

The call was strongly positive, driven by statistically significant and clinically meaningful phase III LUCIDITY results, a planned NDA submission by year-end, substantial funding, and progress toward a potential 2027 launch. The company also reported positive pipeline and commercial developments. The main negatives were higher operating expenses and the early stage of payer, pricing, label, expanded-access, and certain pipeline discussions.

Positive Updates

Positive Phase III LUCIDITY Results
Avexitide met the pre-specified primary endpoint in the phase III LUCIDITY trial, demonstrating a 55% reduction in the composite rate of level two and level three hypoglycemic events compared with placebo, with a P-value of 0.000003. The trial also met all secondary endpoints with consistent, highly statistically significant, and clinically meaningful reductions.

Negative Updates

Higher Operating Expenses
Total operating expenses were $49.7 million in the quarter, up 38% from the same period in 2025.

Company Guidance

Management remains on track to submit the avexitide NDA to the FDA by the end of this year, with a potential approval and launch in 2027; it is targeting a 2027 IND filing for AMX0318, expects payer information exchanges to begin in the first quarter of the year, and expects a good concentration up front for launch that will build over time as educational efforts expand. The company estimates approximately 160,000 people living with PBH in the U.S., including approximately 118,000 people estimated to have received Roux-en-Y gastric bypass surgery and approximately 48,000 people estimated to have received sleeve gastrectomy; it also said its estimates are that about 120,000 of the 160,000 currently had Roux-en-Y gastric bypass. Management said it will not give interim EAP numbers, it is too early to discuss persistency rates, and it is little bit early to discuss the specifics on pricing.

Amylyx Pharmaceuticals Inc Financial Statement Overview

Summary

Operating fundamentals are weak: revenue fell from ~$380.8M (2023) to ~$87.4M (2024) and then to $0 in 2025 and TTM, with large net losses in 2024–TTM and deeply negative operating/free cash flow in TTM (about -$129.9M/-$130.0M). The key offset is balance-sheet strength with very low leverage and sizable equity, providing flexibility despite poor profitability.

Income Statement

18Very Negative

Balance Sheet

72Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue0087.37M380.79M22.23M0
Gross Profit-108.00K-525.00K45.22M355.35M19.24M0
EBITDA-160.97M-144.16M-290.98M55.38M-197.11M-87.88M
Net Income-163.19M-144.74M-301.74M49.27M-198.38M-87.93M
Balance Sheet
Total Assets786.79M332.64M193.63M517.45M391.45M105.61M
Cash, Cash Equivalents and Short-Term Investments768.13M316.98M176.50M371.36M346.94M96.12M
Total Debt4.94M5.96M1.98M4.24M6.28M0
Total Liabilities33.06M27.39M28.87M84.02M50.85M256.78M
Stockholders Equity753.74M305.26M164.76M433.43M340.61M-151.17M
Cash Flow
Free Cash Flow-130.02M-123.48M-167.80M10.68M-182.40M-75.15M
Operating Cash Flow-129.88M-123.34M-167.65M11.92M-179.87M-74.80M
Investing Cash Flow-409.73M14.04M75.65M92.05M-238.99M-46.41M
Financing Cash Flow554.65M257.03M348.00K3.54M431.79M158.51M

Amylyx Pharmaceuticals Inc Technical Analysis

Technical Analysis SentimentNeutral
Last Price26.20

Price Trends

50DMA29.28Negative
100DMA27.05Negative
200DMA20.99Positive

Market Momentum

MACD-0.11Positive
RSI40.87Neutral
STOCH10.46Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Neutral. The current price of 26.20 is below the 20-day moving average (MA) of 28.78, below the 50-day MA of 29.28, and above the 200-day MA of 20.99, indicating a neutral trend. The MACD of -0.11 indicates Positive momentum. The RSI at 40.87 is Neutral, neither overbought nor oversold. The STOCH value of 10.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AMLX.

Amylyx Pharmaceuticals Inc Risk Analysis

Amylyx Pharmaceuticals Inc disclosed 91 risk factors in its most recent earnings report. Amylyx Pharmaceuticals Inc reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Beginning January 1, 2027, we will no longer qualify as a smaller reporting company, which will increase our costs and demands on management.Q3, 2026
2.We expect to generate significant losses for the foreseeable future.Q3, 2026
3.Intellectual property discovered through government funded programs may be subject to federal regulations such as "march-in" rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our future exclusive rights and limit our ability to contract with non-U.S. manufacturers.Q3, 2026

Amylyx Pharmaceuticals Inc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AMLX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HRMYHRMY77Outperform$1.94B10.7518.55%―19.79%-4.89%
BHVNBHVN59Neutral$1.95B-3.34-2271.87%――49.16%
AMLXAMLX54Neutral$3.42B-18.75-41.54%――19.61%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BCRXBCRX49Neutral$1.93B-5.4194.36%―60.30%-3028.57%
DNTHDNTH45Neutral$4.73B2799.33-3.87%―-11.70%-14.33%
PHVSPHVS41Neutral$2.23B-10.38-67.76%――2.74%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%AMLXBCRXDNTHHRMYPHVSBHVNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AMLX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AMLXAmylyx Pharmaceuticals, Inc.26.2011.5378.60%
BCRXBioCryst Pharmaceuticals7.320.355.02%
DNTHDianthus Therapeutics, Inc.84.8343.38104.66%
HRMYHarmony Biosciences Holdings, Inc.32.98-1.33-3.88%
PHVSPharvaris N.V.31.666.8327.51%
BHVNBiohaven Ltd.13.653.9640.87%

Amylyx Pharmaceuticals Inc Corporate Events

Business Operations and Strategy

Amylyx inks long-term manufacturing deal for avexitide

Positive
Sep 8, 2026

On September 8, 2026, Amylyx Pharmaceuticals entered into a long‑term manufacturing and supply agreement with Bachem Americas, and on September 1, 2026, it signed a term sheet with Polypeptide Group AG to secure commercial‑scale production of avexiti...

Business Operations and StrategyPrivate Placements and Financing

Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide

Positive
Aug 20, 2026

On August 19, 2026, Amylyx Pharmaceuticals Inc. entered into an underwriting agreement with a syndicate of banks to issue and sell 14,090,000 shares of common stock at $35.50 per share, with an additional 2,113,500 shares available under a 30-day opt...

Business Operations and StrategyProduct-Related Announcements

Amylyx Highlights Positive Phase 3 Avexitide LUCIDITY Results

Positive
Aug 18, 2026

On August 18, 2026, Amylyx Pharmaceuticals hosted a conference call with investors and analysts to present positive topline data from its Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia after Roux-en-Y gastric bypass surgery. The m...

Business Operations and StrategyProduct-Related Announcements

Amylyx announces positive Phase 3 LUCIDITY avexitide results

Positive
Aug 18, 2026

On August 18, 2026, Amylyx reported positive topline Phase 3 results from its LUCIDITY trial of avexitide in post-bariatric hypoglycemia after Roux-en-Y gastric bypass surgery. The 78-patient study met its FDA-agreed primary endpoint, showing a 55% r...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026